Tag Archives: health insurance

Messaging in Healthcare: Making Sound and Fury Signify Something

by Les Funtleyder Recently, there was a bit of a dust-up over whether it was appropriate for the Secretary of Health and Human Services (HHS) to engage the National Football League (NFL) to help HHS with the process of drumming-up enrollment for health insurance exchanges. In the end, the NFL and other sports leagues decided […]
Posted in Market Access, Patient Communication, patient education, Strategy | Also tagged , , , , , , | 1 Comment

Those Amazing 'Gold Plated, Cadillac Care' Drug Programs

by Tom Norton Not too many years ago, while employed by one of America’s leading Rx manufacturers, I remember stepping up to a retail drug store counter to pick up a prescription.  As the pharmacist handed me my script, he said, “Wow.  I don’t know what kind of health insurance you have, but I have […]
Posted in FDA, Global, Guest Blog, healthcare, Legal, Market Access, pricing, Regulatory, Strategy | Also tagged , , , , , , , , , , , , , , , , , | Leave a comment

FT Healthcare Conference: Society as Stakeholder

Speakers at the 2nd annual Financial Times US Healthcare and Life Sciences conference in New York last week discussed the cost of health, and the implications of an increasingly vocal and influential stakeholder group: the local populace. After opening remarks from Andrew Jack, FT’s prolific pharmaceuticals correspondent, Pfizer CEO Ian Read took the stage at […]
Posted in Europe, Events, Global, healthcare, leadership, Market Access, Orphan Drugs, People, pricing, R&D, Regulatory, Strategy, Technology | Also tagged , , , , , , , , , , , , , , , , | Leave a comment

Are US and Canadian Rx Policies Converging?

by Tom Norton As the US pharmaceutical industry anxiously watches the rapid onset of Obamacare, certainly one of the more pressing issues is the debate over the number of drugs that will be reimbursed in each therapeutic class under the Essential Health Benefits (EHB) program.  To say that this is a critical concern for the […]
Posted in Global, Guest Blog, healthcare, Legal, Market Access, Strategy | Also tagged , , , , , | Leave a comment

Specialty Drugs and Reimbursement

To maximize return on investment, pharma must think strategically about reimbursement channels and how new specialty products will perform in one versus another. By 2018, the amount health insurers spend per person on specialty, or biologic drugs, will equal or surpass the amount spent on traditional products, according to a new report. With the emergence […]
Posted in Biotech, Strategy | Also tagged , , | Leave a comment
  • Categories

  • Meta